ALX-0761

C4X Discovery received an €8 million milestone payment from Sanofi reflecting further preclinical progress in their oral IL-17A inhibitor programme for inflammatory diseases.

Zura Bio has initiated the Phase II TibuSHIELD trial evaluating tibulizumab, a first-of-its-kind dual inhibitor targeting both BAFF and IL-17A pathways in patients with moderate to severe hidradenitis suppurativa.

DelveInsight's 2025 report reveals a robust pipeline with 24+ companies developing 24+ therapies for hidradenitis suppurativa, a chronic inflammatory skin condition affecting hair follicles.

UCB's Bimzelx (bimekizumab-bkzx) demonstrated sustained complete skin clearance in 67.7% of patients with moderate-to-severe plaque psoriasis after five years of treatment, according to Phase III clinical trial data.

UCB's Bimzelx achieves remarkable milestone with five FDA approvals in one year, offering new treatment options for psoriasis, hidradenitis suppurativa, and various arthritic conditions.